Navigation Links
IDM Pharma Provides Update of Product Pipeline and Announces Plans to Evaluate Strategic Alternatives for the Company
Date:12/14/2007

IRVINE, Calif., Dec. 14 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today provided an update of the three lead programs in its product pipeline, mifamurtide (L-MTP-PE), UVIDEM(R) and IDM-2101.

Mifamurtide (L-MTP-PE)

IDM Pharma continues to work with European regulators responding to questions and issues raised by the Committee for Medicinal Products for Human Use (CHMP) in the most recent communications received by the company regarding the marketing authorization application (MAA) for L-MTP-PE filed by the Company. To allow the necessary time to respond to these most recent questions, the Company has asked for and been granted a clock stop, or extension, of approximately one month. The Company now expects to receive an opinion on the approvability of the MAA for L-MTP-PE by late January 2008.

In the U.S., the Company has been working with external experts and advisors to gather patient follow up data from the Phase 3 clinical trial of L-MTP-PE conducted by the Children's Oncology Group (COG) and to respond to other questions in the not approvable letter the Company received from the Food and Drug Administration (FDA).

Because the COG had closed the Phase 3 trial in March 2007, in which the patients completed treatment in 1997, a number of challenges have been encountered in collecting the follow up data, including trial sites requiring approval from their Investigational Review Boards (IRBs) prior to searching for and providing additional patient data. These factors have caused significant delays in the Company's attempt to gather this data. The COG has now agreed to assist the Company in collecting this patient follow up data. Because of the challenges of the data collection efforts and to respo
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 For the pharmaceutical industry, ... dealing with payers. Likewise, the importance of the managed markets ... only continue to grow as payer formularies and provider networks ... At the same time, managed markets leaders must ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015 Research and Markets ... of the "Urinary Catheters Market (Indwelling or Foley ... - Global Industry Analysis, Size, Share, Growth, Trends and ... , At present, the global market ...
(Date:1/23/2015)... Pa. , Jan. 23, 2015  MedScope ( www.medscope.org ... been nominated for a 2015 Connected World ... Emergency Response System (mPERS), that can be used anywhere, ... technology partner.  In nominating MedScope, ...
Breaking Medicine Technology:As Payer Influence Rises, Pharmaceutical Companies work to Optimize the Managed Markets Function 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2
... 7, 2011 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ... will present a company overview at Roth,s 23rd Annual OC ... p.m. PT at the Ritz Carlton Laguna Niguel.   ... available on the "Investors & Media" section of the Company,s ...
... Mass., March 7, 2011 Boston Scientific Corporation ... has received CE Mark for its OMEGA™ Platinum ... coronary stenting technology.  It incorporates Boston Scientific,s unique ... stenting and is intended to provide interventional cardiologists ...
Cached Medicine Technology:Boston Scientific Announces European Approval and Launch of OMEGA™ Platinum Chromium Stent System 2Boston Scientific Announces European Approval and Launch of OMEGA™ Platinum Chromium Stent System 3Boston Scientific Announces European Approval and Launch of OMEGA™ Platinum Chromium Stent System 4
(Date:1/22/2015)... City, Florida (PRWEB) January 22, 2015 IsoComforter, ... cold therapy machine with patented IsoTube design to treat specific ... has introduced the most progressive and easy to use patented ... treat post-operative and sports related orthopedic and muscle injuries. ...
(Date:1/22/2015)... Payday lending practices in four southern ... financial distress to the states that permit them, according ... Center on Race and Wealth. , While they generate ... loans at the same time substantially depress economic activity, ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... component of overall health care gains momentum worldwide, Rev. ... York-based HealthCare Chaplaincy Network (HCCN), will be the ... advance spiritual care in Israel’s public health system. , The ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a ... insurance policy . , Some types of vehicles cannot be ... newly released blog post to see if their vehicle qualifies for ... are some of the cars that cannot be covered by a ...
(Date:1/22/2015)... VA (PRWEB) January 22, 2015 Step ... power at the Science Museum of Virginia. Wicked Plants, ... , Wicked Plants unearths 75 poisonous, carnivorous and diabolical ... through each room to uncover the biochemical, physical and ...
Breaking Medicine News(10 mins):Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... challenges in managing their blood glucose levels, and it ... system providing continuous real-time glucose readings. Today, The Endocrine ... on settings where patients are most likely to benefit ... way to self-check blood glucose levels is to prick ...
... caught in its early stages, prostate cancer is treatable ... threshold, the disease becomes largely resistant to current treatments. ... of cancer biologists $9.55 million over five years to ... progresses to the therapy-resistant state. The Program Project ...
... Netherlands, 11 October 2011 Alzheimer,s disease (AD) is ... the world. A new supplement to the ... clearly shows that multiple imaging systems are now available ... "Alzheimer,s disease is now seen as a ...
... published in the October issue of the Journal of ... breast malignancies accounting for 0.5 to one percent of all ... patients. Population-based estimates indicate that the incidence of malignant phyllodes ... frequencies in Hispanic women. Previous studies have focused on ...
... the start of 2011, the active ingredient ticagrelor can ... (ASA) to avoid blood clots in patients with acute ... Quality and Efficiency in Health Care (IQWiG) has now ... coronary syndrome (ACS) in comparison with conventional drugs. This ...
... team of researchers, Gloria Petersen, Ph.D. , of ... California, San Francisco, and Susan Wolf, J.D., of the University ... the National Cancer Institute and the National Human Genome Research ... genetic research results, such as DNA test results, from tissue ...
Cached Medicine News:Health News:Experts find continuous glucose monitoring beneficial in maintaining target blood glucose levels 2Health News:$9.55 million NCI grant targets the resistance of advanced prostate cancer 2Health News:Advances in brain imaging can expedite research and diagnosis in Alzheimer's disease 2Health News:Advances in brain imaging can expedite research and diagnosis in Alzheimer's disease 3Health News:Hispanic women have higher incidence of rare breast tumor 2Health News:Ticagrelor: Considerable added benefit for specific patients 2Health News:Ticagrelor: Considerable added benefit for specific patients 3Health News:Ticagrelor: Considerable added benefit for specific patients 4